Zura Bio Ltd Ordinary Shares - Class A ZURA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ZURA is a good fit for your portfolio.
News
-
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
-
Zura Bio Announces Robert Lisicki as CEO and Director
-
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
-
Zura Bio Announces Participation at March Conferences
-
Zura Bio Announces Participation at February Investor Conferences
-
Zura Bio Inks License With Eli Lilly, Sets $80 Million Private Placement
Trading Information
- Previous Close Price
- $3.62
- Day Range
- $3.68–4.85
- 52-Week Range
- $2.00–14.00
- Bid/Ask
- $4.25 / $4.46
- Market Cap
- $274.86 Mil
- Volume/Avg
- 897,979 / 314,661
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 15
- Website
- https://www.zurabio.com
Comparables
Valuation
|
Metric
|
ZURA
|
GHRS
|
PNT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 11.36 |
Price/Book Value | 2.66 | 2.50 | 3.12 |
Price/Sales | — | — | 5.50 |
Price/Cash Flow | — | — | 13.90 |
Price/Earnings
ZURA
GHRS
PNT
Financial Strength
|
Metric
|
ZURA
|
GHRS
|
PNT
|
|---|---|---|---|
Quick Ratio | 4.92 | 24.14 | 9.01 |
Current Ratio | 4.97 | 24.49 | 9.14 |
Interest Coverage | — | −706.38 | — |
Quick Ratio
ZURA
GHRS
PNT
Profitability
|
Metric
|
ZURA
|
GHRS
|
PNT
|
|---|---|---|---|
Return on Assets (Normalized) | −71.08% | −12.75% | 20.67% |
Return on Equity (Normalized) | −139.85% | −13.12% | 23.56% |
Return on Invested Capital (Normalized) | −99.89% | −16.87% | 23.38% |
Return on Assets
ZURA
GHRS
PNT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vvggmhrbt | Qcvk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tlzqwwgn | Tyfqzcd | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ksdhmkf | Qhvvgg | $97.8 Bil | |
MRNA
| Moderna Inc | Spxfwjffw | Tzsj | $41.3 Bil | |
ARGX
| argenx SE ADR | Sckyhjldb | Dgx | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Glngqtxxc | Qjjt | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jgfblwlp | Nbjps | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sppthvgx | Gbxbnqb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fgpqybhc | Pkvfc | $12.5 Bil | |
INCY
| Incyte Corp | Flcjbchpq | Jvxblj | $11.6 Bil |